C-KJESEidos Therapeutics
genetic disease medicines, TTR stabilization, clinical research
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KJES
C-KJESC-KJESgenetic disease medicines, TTR stabilization, clinical research
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Eidos Therapeutics genetic disease medicines, TTR stabilization, clinical research
BridgeBio presents research and patient resources for conditions including ATTR-CM, achondroplasia, ADH1, ATTRv, Canavan disease, hypochondroplasia, and LGMD2I/R9. The supplied page explains ATTR-CM as a rare, under-diagnosed, life-threatening disease caused by destabilization of transthyretin proteins, leading to amyloid fibril buildup in the heart. The site also lists medicines and pipeline items including Attruby (acoramidis) and NULIBRY (fosdenopterin).
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Eidos Therapeutics — Near-term readout · Bottom quartile. Derived deterministically from 6 extracted project(s). Most-advanced status: approved. Band: near_readout. Modifiers: +5 depth (2 programs at approved).…
Source: Deterministic